Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
出版年份 2021 全文链接
标题
Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor
作者
关键词
-
出版物
Journal of Clinical Medicine
Volume 10, Issue 18, Pages 4221
出版商
MDPI AG
发表日期
2021-09-18
DOI
10.3390/jcm10184221
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
- (2020) Takaya Ikeda et al. Thoracic Cancer
- Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201)
- (2019) Minoru Fukuda et al. LUNG CANCER
- Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer
- (2019) Midori Shimada et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies
- (2019) Jessica A. Hellyer et al. LUNG CANCER
- Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy
- (2018) Mika Saigusa et al. Oncology Research and Treatment
- Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer
- (2017) Shinnosuke Takemoto et al. Thoracic Cancer
- Myeloid Growth Factors
- (2017) Jeffrey Crawford et al. Journal of the National Comprehensive Cancer Network
- A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer
- (2016) H. Yoshioka et al. ANNALS OF ONCOLOGY
- Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer
- (2015) Kyoichi Kaira et al. International Journal of Clinical Oncology
- Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L
- (2015) Tetsuya Abe et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702
- (2015) Akira Inoue et al. LUNG CANCER
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. JOURNAL OF CLINICAL ONCOLOGY
- A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)
- (2014) Haruyasu Murakami et al. LUNG CANCER
- The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials
- (2013) G. H. Lyman et al. ANNALS OF ONCOLOGY
- Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial
- (2012) Chiyoe Kitagawa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Amrubicin Monotherapy for Patients with Previously Treated Advanced Large-cell Neuroendocrine Carcinoma of the Lung
- (2011) H. Yoshida et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- (2010) M.S. Aapro et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
- (2010) David S. Ettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
- (2010) Robert Jotte et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401)
- (2010) Hiroyasu Kaneda et al. Journal of Thoracic Oncology
- A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer
- (2009) Kyoichi Kaira et al. LUNG CANCER
- Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
- (2008) Akira Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started